Skip to main content

Table 2 Surgical treatment and complications

From: The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature

Characteristics All patients
23 (100%)a
NR
7 (30%)
PR
10 (43%)
TR
6 (26%)
p valueb
Radiotherapy      0.822
 45 Gy 1 (4) 0 1 (10) 0  
 45 Gy + 5.4 Gy 21 (91) 6 (86) 9 (90) 6 (100)  
 50.5 Gy 1 (4) 1 (14) 0 0  
Chemotherapy      3.2e−05
 Xeloda® 22 (96) 7 (100) 9 (90) 6 (100)  
 5-FU 1 (4) 0 1 (10) 0  
Radiodermatitis      0.962
 − 7 (30) 2 (29) 3 (30) 2 (33)  
 Non-severe 13 (57) 4 (57) 5 (50) 4 (67)  
 Severe 3 (13) 1 (14) 2 (20) 0  
Proctitis      0.211
 + 11 (48) 2 (29) 7 (70) 2 (33)  
 − 12 (52) 5 (71) 3 (30) 4 (67)  
Colitis      1
 + 0 0 0 0  
 − 23 (100) 7 (100) 10 (100) 6 (100)  
Mucositis      1
 + 0 0 0 0  
 − 23 (100) 7 (100) 10 (100) 6 (100)  
Surgical resection type      0.004
 Low anterior 17 (74) 7 (100) 8 (80) 2 (33)  
 Abdomino-perineal 2 (9) 0 2 (20) 0  
 Endo-anal 1 (4) 0 0 1 (17)  
 Refused 3 (13) 0 0 3 (50)  
Surgery delay      
 Median 8.6 ± 2.8 9.3 ± 2.7 8.3 ± 3.1 8.1 ± 2.6  
 Range 1.4–13.1 5.3–13.1 1.4–12.9 6.0–11.0  
  1. 5-FU 5-fluorouracil, Gy Gray, NR non-responders, PR partial responders, TR total responders
  2. aFirst number: number of patients; number in parentheses: percentage of patients
  3. bThe p value is obtained by Fisher’s exact test and is considered significant when p value < 0.05